Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Merck
Medtronic
Argus Health
Baxter
QuintilesIMS
US Army
Cipla
McKesson

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,258,132

« Back to Dashboard

Which drugs does patent 8,258,132 protect, and when does it expire?

Patent 8,258,132 protects EMEND and is included in two NDAs.

This patent has forty-one patent family members in thirty-five countries.
Summary for Patent: 8,258,132
Title:Pharmaceutical composition of a tachykinin receptor antagonist
Abstract: The present invention is directed to novel pharmaceutical compositions of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phen- yl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine. The pharmaceutical compositions of this invention useful in the treatment or prevention of disorders such as psychiatric disorders including depression and anxiety, inflammatory diseases and emesis.
Inventor(s): Bosch; H. William (Bryn Mawr, PA), Liversidge; Elaine (West Chester, PA), Shelukar; Suhas D. (Lansdale, PA), Thompson; Karen C. (Lansdale, PA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:10/317,948
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 8,258,132

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up Y PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING ➤ Sign Up
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up Y FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY ➤ Sign Up
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No ➤ Sign Up ➤ Sign Up Y FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY ➤ Sign Up
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No ➤ Sign Up ➤ Sign Up Y PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Accenture
Citi
Julphar
UBS
US Army
Cerilliant
Federal Trade Commission
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.